| 09:15-09:55 | Plenary 1: siRNA Therapeutics |
|---|---|
| 09:15-09:55 | PL01 Mano Manoharan (Alnylam Pharmaceuticals, USA) |
| 09:55-11:10 | Session 1. siRNA Therapeutics |
|---|---|
| 09:55-10:20 | S01-1 Development of New Molecular Technologies for siRNA Therapeutics Takeshi Wada (Tokyo University of Science, Japan) |
| 10:20-10:45 | S01-2 Harnessing the Promise of RNA Therapeutics Jihye Park (Novo Nordisk, USA) |
| 10:45-11:10 | S01-3 Expanding RNAi Therapeutics Beyond the Liver: An Integrated OASIS Platform for Hepatic and Extrahepatic Delivery June Hyun Park (OliX Pharmaceuticals, Korea) |
| 11:30-12:35 | Session 2. mRNA Therapeutics: Innovation & Production |
|---|---|
| 11:30-11:55 |
S02-1 Chemical Synthesis and Engineering of mRNA for Next-Generation Nucleic Acid Therapeutics Hiroshi Abe (Nagoya University, Japan) |
| 11:55-12:20 |
S02-2 Transforming Pulmonary Therapeutics with a Novel Lung-Selective Ionizable Lipid and Polymer-Based Stability Enhanced Nanoshell (SENSTM) Technology Optimized for Inhaled and Systemic Administrations Helen Cho (Samyang Biopharm, Korea) |
| 12:20-12:35 |
S02-3 Chemical Engineering of mRNA for Enhanced Translation and Therapeutic Performance Young Jun Seo (Elonova, Korea) |
| 12:35-13:35 | Lunch Seminar 1 [LS1] |
|---|---|
| 12:35-13:35 | LS1 TBD |
| 13:35-14:15 | Plenary 2: RNA Biology |
|---|---|
| 13:35-14:15 |
PL02 Noncanonical Tails: Functions, Mechanisms, and Therapeutic Potential V. Narry Kim (Seoul National University / IBS, Korea) |
| 14:15-15:35 | Session 3. RNA Biology & Chemistry |
|---|---|
| 14:15-14:40 | S03-1 Potent and Specific siRNA Design: From Sequence Rules to Structure-Guided Precision Therapeutics Kumiko Ui-Tei (Institute of Science Tokyo, Japan) |
| 14:40-15:05 | S03-2 TBD |
| 15:05-15:20 | S03-3 Decoding RNA-RBP Dynamics to Control RNA Immunogenicity Yoosik Kim (KAIST, Korea) |
| 15:20-15:35 | S03-4 Synthesis and Biological Evaluation of 3′-C-Fluoromethyl-8-azaadenosine as a Novel Hit Targeting ADAR-Mediated RNA Editing Jinha Yu (Ewha Womans University, Korea) |
| 15:55-17:25 | Session 4. Innovation in Oligonucleotide Therapeutics |
|---|---|
| 15:55-16:20 | S04-1 Ron Batra (Dyne Therapeutics, USA) |
| 16:20-16:45 | S04-2 RNAa: From Bench to Bedside—A 20-Year Journey Long-Cheng Li (Ractigen Therapeutics, China) |
| 16:45-17:10 |
S04-3 Engineered Cysteine AOC Process Development: DAR Control, Orthogonal Analytics, and Site-Level Characterisation Kris S. Choi / Mahnseok Kye (ST Pharm, Korea) |
| 17:10-17:25 | S04-4 Extrahepatic Delivery of Oligonucleotide Therapeutics Using DNA Nanostructures Dae-Ro Ahn (KIST, Korea) |